About US
Contact us
-
Pfizer scores FDA nod for biosim to AbbVie's Humira, but it'll have to wait till 2023 to launchAbbVie is preparing for the costly U.S. loss of Humira exclusivity in 2023, and now there’s another pharma giant that has scored a biosimilar nod. Pfizer’sAbrilada, abiosimto AbbVie’smegablockbusterH2019/11/8
-
Bristol-Myers’ $74B Celgene buy wins antitrust nod in FTC party-line split voteIndustry watchers largely expected that Bristol-Myers Squibb and Celgene would win U.S. antitrust clearance for their $74 billion merger. But what’s perhaps unexpected is that the permission was not2019/11/8
-
Oklahoma judge chops $107M from Johnson & Johnson's opioid verdictAfter losing thenation’s first major opioid trial in Oklahoma this summer,Johnson & Johnson lawyers sought to reduce the company'sliability. Now, a judge has chopped more than $100 million off th2019/11/7
-
AHA: Amarin's Vascepa halts progression of arterial plaque in key studyPHILADELPHIA—One year after a cardiovascular outcomes study for Amarin's Vascepa took the American Heart Association's (AHA's) Scientific Sessions by storm, the fish-oil derivativeis back—and on the2019/11/7
-
AbbVie may count on Allergan's Botox for post-merger growth. But what else?With a $63 billion merger nearing approval, AbbVie is counting onAllergan and its cash-cow Botox to boost sales—and that superstar could be a long-term winner. But not every drug in Allergan's stable2019/11/6
-
Takeda's emerging markets cull reaches Russia with $660M Stada selloffAfter Stada CEO Peter Goldschmidtbrushed offthe possibility of a deal for some Takeda drugs in western Europe, the German generics player has laid hands on a differentTakeda portfolio—and it's the la2019/11/6
-
After years-long delay, Novartis' Sandoz finally wins Neulasta biosimilar nodBack in 2016, FDA stiff-armed Novartis and its biosimilar version of Amgen's Neulasta. After three long years and one batch of new study data, the company finally has its approval and and plans to la2019/11/5
-
China approves a new, home-grown Alzheimer's drug—and questions immediately followSince Allergan’s Namenda FDA nod in late 2003, the world hasn’t seen an approved Alzheimer’s disease new drug for 17 years. That drought was brokenSaturday, not by a Western biopharma bigwig, but by2019/11/5
-
Eli Lilly, Boehringer shake up diabetes deal to focus on hot property JardianceEli Lilly and Boehringer Ingelheim have stormed to a market-leading position with their SGLT-2 diabetes drug Jardiance, and they’re pushing that med to the forefront of their longstanding diabetes pa2019/11/4
-
Sanofi pays $315M to settle claims it delayed Lemtrada to avoid investor payoutsSanofi has been battling claims that it dragged its feet on multiple sclerosis (MS) drug candidate Lemtrada, acquired in its Genzyme buyout, to avoid follow-up payments to investors. But now, thedrug2019/11/4